Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare eye disease: personalized drug schedule shows promise

NCT ID NCT05666804

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a personalized treatment plan using the drug brolucizumab for people with a specific eye condition called polypoidal choroidal vasculopathy (PCV). The goal was to see if adjusting the treatment schedule based on each person's needs could maintain or improve vision while reducing how often they need injections. The study involved 148 adults aged 50 and older who had not been treated for this condition before, and it lasted 60 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACULAR POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder Polypoidal Choroidal Vasculopathy retinal disorder scotoma vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MACULAR POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)

Contacts and locations

Locations

  • Novartis Investigative Site

    Daegu, Dalseo Gu, 42602, South Korea

  • Novartis Investigative Site

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    Daejeon, Korea, 35015, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 02447, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Busan, 48108, South Korea

  • Novartis Investigative Site

    Busan, 49241, South Korea

  • Novartis Investigative Site

    Busan, 613-815, South Korea

  • Novartis Investigative Site

    Daegu, 705703, South Korea

  • Novartis Investigative Site

    Gwangju, 61469, South Korea

  • Novartis Investigative Site

    Seoul, 01000, South Korea

  • Novartis Investigative Site

    Seoul, 01869, South Korea

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Seoul, 06273, South Korea